Also listed on Genewave, an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Apr 8, 2026 (Royal Bank of Canada).
Term ends Oct 31, 2035 · High confidence
20-year base term ends Nov 27, 2034
Held by Gen-Probe Incorporated
Filed Apr 10, 2020 as application 16/845,631 · Granted Nov 14, 2023
Base term plus 509 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2014
2035
Clock starts
Nov 27, 2014
Nov 27, 2014
Term ends
Oct 31, 2035
Oct 31, 2035
Granted
Nov 14, 2023
Nov 14, 2023
base term
patent term adjustment
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
509
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,654,039.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 509 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 27, 2014, when application PCT/EP2014/075868, the earliest non-provisional in its chain, was filed (this one was filed Apr 10, 2020) | Nov 27, 2034 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +509 days, USPTO patent term adjustment record | Apr 19, 2036 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,654,039) | capped to Oct 31, 2035 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 31, 2035 | High confidence |
This family
| US 10,654,039 | In force Oct 2035 | Oct 2035 |
| US 11,813,609 | this patent Oct 2035 | Oct 2035 |
| US 12,275,009 | In force no later than Nov 2034 | no later than Nov 2034 |
| Application 18/763,917 | Pending not computed | not computed |
| Application 19/027,187 | Pending not computed | not computed |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 10, 2020 Reel 52366, frame 955 | Marcy, Yann; Artigue, Marc; Le Masne, Quentin; Marq, Kevin | Genewave | Assignment of Assignor's Interest |
| Aug 26, 2024 Reel 68400, frame 684 | Mobidiag Oy | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Aug 26, 2024 Reel 68788, frame 810 | Genewave SAS | Mobidiag Oy | Assignment of Assignor's Interest |
| Mar 30, 2026 Reel 74227, frame 597 | Mobidiag Oy | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Mar 30, 2026 Reel 75325, frame 966 | Genewave | Mobidiag Oy | Assignment of Assignor's Interest |
| Apr 8, 2026 Reel 75462, frame 440 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Royal Bank of Canada, as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75926, frame 339 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Oct 2035
Term ends Oct 31, 2035. Maintenance fees still fall due before then
Note
The 509 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,654,039.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.